(one-HOur Low-cost Multipurpose highly Efficient System)
ToloBio first discovered that the CRISPR-Cas12 protein has efficient "trans-cleavage activity" and developed the "HOLMES" (one-HOur Low-cost Multipurpose highly Efficient System) nucleic acid rapid detection platform. CRISPR-Dx have been recognized as "the next-generation molecular diagnostic technology" by SCIENCE journal.
0
%
Shorter Turnaround Time
0
%
Higher Specificity
0
%
Lower Cost
0
%
Higher Sensitivity
合作伙伴
吐露港生物与美国 SHERLOCK BIOSCIENCES(创始人:张锋)就Cas12和Cas13的诊断技术达成专利交叉授权合作。吐露港生物愿携手创新型IVD企业，加快推进CRISPR诊断产业的蓬勃发展。
Sherlock Biosciences
伯杰医疗
华大基因
源景泰科
臻准生物
